1. Home
  2. ACM vs VTRS Comparison

ACM vs VTRS Comparison

Compare ACM & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AECOM

ACM

AECOM

HOLD

Current Price

$96.90

Market Cap

17.6B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$13.23

Market Cap

14.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACM
VTRS
Founded
1980
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.6B
14.8B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
ACM
VTRS
Price
$96.90
$13.23
Analyst Decision
Strong Buy
Hold
Analyst Count
9
6
Target Price
$134.00
$11.50
AVG Volume (30 Days)
1.2M
8.0M
Earning Date
02-09-2026
02-26-2026
Dividend Yield
1.28%
3.63%
EPS Growth
42.91
N/A
EPS
4.22
N/A
Revenue
$16,139,622,000.00
$14,124,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.75
$1.18
P/E Ratio
$20.27
N/A
Revenue Growth
0.21
N/A
52 Week Low
$85.00
$6.85
52 Week High
$135.52
$13.49

Technical Indicators

Market Signals
Indicator
ACM
VTRS
Relative Strength Index (RSI) 41.38 66.94
Support Level $94.46 $12.55
Resistance Level $99.12 $13.31
Average True Range (ATR) 2.55 0.34
MACD 0.44 -0.01
Stochastic Oscillator 38.38 79.23

Price Performance

Historical Comparison
ACM
VTRS

About ACM AECOM

Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: